

Ronald A Ghossein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8523130/publications.pdf>

Version: 2024-02-01

158
papers

17,601
citations

16451

64
h-index

14208

128
g-index

163
all docs

163
docs citations

163
times ranked

12910
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated Genomic Characterization of Papillary Thyroid Carcinoma. <i>Cell</i> , 2014, 159, 676-690.	28.9	2,318
2	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 1023.	7.1	1,192
3	Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. <i>Journal of Clinical Investigation</i> , 2016, 126, 1052-1066.	8.2	874
4	Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 623-632.	27.0	692
5	Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for <i>BRAF</i> , <i>PIK3CA</i> , and <i>AKT1</i> . <i>Cancer Research</i> , 2009, 69, 4885-4893.	0.9	488
6	Overview of the 2022 WHO Classification of Thyroid Neoplasms. <i>Endocrine Pathology</i> , 2022, 33, 27-63.	9.0	388
7	Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1562-E1566.	3.6	378
8	Follicular variant of papillary thyroid carcinoma. <i>Cancer</i> , 2006, 107, 1255-1264.	4.1	363
9	Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 1015.	2.2	359
10	Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. <i>Endocrine-Related Cancer</i> , 2008, 15, 1069-1074.	3.1	351
11	Relief of Feedback Inhibition of <i>HER3</i> Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in <i>BRAF</i> -Mutant Thyroid Carcinomas. <i>Cancer Discovery</i> , 2013, 3, 520-533.	9.4	328
12	Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct <i>BRAF</i> and <i>RAS</i> mutation patterns. <i>Modern Pathology</i> , 2010, 23, 1191-1200.	5.5	325
13	Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional <i>BRAF</i> activation. <i>Journal of Clinical Investigation</i> , 2011, 121, 4700-4711.	8.2	305
14	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. <i>Nature Medicine</i> , 2019, 25, 767-775.	30.7	282
15	Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules. <i>JAMA Surgery</i> , 2018, 153, 817.	4.3	275
16	Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis. <i>Cancer</i> , 2006, 106, 1286-1295.	4.1	266
17	<i>AXL</i> Mediates Resistance to <i>PI3K</i> Inhibition by Activating the <i>EGFR/PKC/mTOR</i> Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. <i>Cancer Cell</i> , 2015, 27, 533-546.	16.8	263
18	Integrated Genomic Analysis of <i>Art4</i> Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. <i>Cancer Cell</i> , 2018, 34, 256-270.e5.	16.8	195

#	ARTICLE	IF	CITATIONS
19	Histopathologic characterization of radioactive iodineâ€refractory fluorodeoxyglucoseâ€positron emission tomographyâ€positive thyroid carcinoma. <i>Cancer</i> , 2008, 113, 48-56.	4.1	184
20	Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 1615-1620.	7.1	183
21	Genomic Dissection of Hurthle Cell Carcinoma Reveals a Unique Class of Thyroid Malignancy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E962-E972.	3.6	169
22	Vemurafenib Redifferentiation of <i>BRAF</i> Mutant, RAI-Refractory Thyroid Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1417-1428.	3.6	165
23	Papillary Thyroid Carcinoma Tall Cell Variant. <i>Thyroid</i> , 2008, 18, 1179-1181.	4.5	158
24	Genome-Wide Appraisal of Thyroid Cancer Progression. <i>American Journal of Pathology</i> , 2002, 161, 1549-1556.	3.8	156
25	Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. <i>Thyroid</i> , 2020, 30, 1505-1517.	4.5	143
26	Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1192-9.	2.0	142
27	Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. <i>Cancer</i> , 1996, 78, 10-16.	4.1	141
28	Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma. <i>Endocrine Pathology</i> , 2016, 27, 205-212.	9.0	140
29	Genome-Wide Profiling of Papillary Thyroid Cancer Identifies MUC1 as an Independent Prognostic Marker. <i>Cancer Research</i> , 2004, 64, 3780-3789.	0.9	137
30	Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects. <i>Thyroid</i> , 2019, 29, 311-321.	4.5	135
31	Hurthle Cell Carcinoma: A Critical Histopathologic Appraisal. <i>Journal of Clinical Oncology</i> , 2001, 19, 2616-2625.	1.6	126
32	Encapsulated Papillary Thyroid Carcinoma: A Clinico-Pathologic Study of 106 Cases with Emphasis on Its Morphologic Subtypes (Histologic Growth Pattern). <i>Thyroid</i> , 2009, 19, 119-127.	4.5	125
33	Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules. <i>Annals of Surgical Oncology</i> , 2015, 22, 3996-4001.	1.5	124
34	Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. <i>Human Pathology</i> , 2015, 46, 657-664.	2.0	121
35	Tall Cell Variant of Papillary Thyroid Carcinoma without Extrathyroid Extension: Biologic Behavior and Clinical Implications. <i>Thyroid</i> , 2007, 17, 655-661.	4.5	119
36	Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland. <i>Cancer</i> , 2006, 106, 1669-1676.	4.1	118

#	ARTICLE	IF	CITATIONS
37	Papillary Thyroid Cancerâ€™ Aggressive Variants and Impact on Management: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 3112-3128.	2.9	115
38	Prognostic factors of recurrence in salivary carcinoma ex pleomorphic adenoma, with emphasis on the carcinoma histologic subtype: a clinicopathologic study of 43 cases. <i>Human Pathology</i> , 2010, 41, 927-934.	2.0	109
39	Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. <i>Thyroid</i> , 2017, 27, 512-517.	4.5	109
40	A Proposal to Redefine Close Surgical Margins in Squamous Cell Carcinoma of the Oral Tongue. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 555.	2.2	109
41	Papillary Thyroid Carcinomas with Cervical Lymph Node Metastases Can Be Stratified into Clinically Relevant Prognostic Categories Using Oncogenic <i>BRAF</i> , the Number of Nodal Metastases, and Extra-Nodal Extension. <i>Thyroid</i> , 2012, 22, 575-584.	4.5	108
42	<i>NF2</i> Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. <i>Cancer Discovery</i> , 2015, 5, 1178-1193.	9.4	107
43	The History of the Follicular Variant of Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 15-22.	3.6	107
44	Consistent <i>PLAG1</i> and <i>HMG2</i> abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts. <i>Human Pathology</i> , 2015, 46, 26-33.	2.0	103
45	Follicular variant of papillary thyroid carcinoma: Genome-wide appraisal of a controversial entity. <i>Genes Chromosomes and Cancer</i> , 2004, 40, 355-364.	2.8	102
46	Prognostic Implications of Papillary Thyroid Carcinoma with Tall-Cell Features. <i>Thyroid</i> , 2014, 24, 662-670.	4.5	98
47	Adrenocortical Adenoma and Carcinoma: Histopathological and Molecular Comparative Analysis. <i>Modern Pathology</i> , 2003, 16, 742-751.	5.5	96
48	A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. <i>Journal of Nuclear Medicine</i> , 2002, 43, 1482-8.	5.0	95
49	Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of <i>MED12</i> and <i>RBM10</i> as Novel Thyroid Cancer Genes Associated with Tumor Virulence. <i>Clinical Cancer Research</i> , 2017, 23, 5970-5980.	7.0	89
50	Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic review. <i>Radiotherapy and Oncology</i> , 2011, 101, 425-430.	0.6	88
51	Detection of Tyrosinase mRNA by Reverse Transcription Polymerase Chain Reaction in Melanoma Sentinel Nodes. <i>Annals of Surgical Oncology</i> , 1999, 6, 232-240.	1.5	85
52	Frequent <i>IDH2</i> R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas. <i>Journal of Pathology</i> , 2017, 242, 400-408.	4.5	83
53	DNA methylation-based classification of sinonasal undifferentiated carcinoma. <i>Modern Pathology</i> , 2019, 32, 1447-1459.	5.5	82
54	Molecular, Morphologic, and Outcome Analysis of Thyroid Carcinomas According to Degree of Extrathyroid Extension. <i>Thyroid</i> , 2010, 20, 1085-1093.	4.5	80

#	ARTICLE	IF	CITATIONS
55	Clinical Significance of Molecular Expression Profiles of H ¹⁴ rthle Cell Tumors of the Thyroid Gland Analyzed via Tissue Microarrays. <i>American Journal of Pathology</i> , 2002, 160, 175-183.	3.8	79
56	Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. <i>Nature Communications</i> , 2017, 8, 1197.	12.8	77
57	Immunohistochemical Detection of Mutated BRAF V600E Supports the Clonal Origin of BRAF-Induced Thyroid Cancers Along the Spectrum of Disease Progression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1414-E1421.	3.6	76
58	Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. <i>Modern Pathology</i> , 2016, 29, 985-995.	5.5	74
59	H ¹⁴ rthle cell carcinoma: A 60-year experience. <i>Annals of Surgical Oncology</i> , 2002, 9, 197-203.	1.5	73
60	Update to the College of American Pathologists Reporting on Thyroid Carcinomas. <i>Head and Neck Pathology</i> , 2009, 3, 86-93.	2.6	73
61	Patterns of recurrence in oral tongue cancer with perineural invasion. <i>Head and Neck</i> , 2018, 40, 1287-1295.	2.0	73
62	Factors Influencing the Basal and Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin in Patients with Metastatic Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 6010-6016.	3.6	72
63	Problems and Controversies in the Histopathology of Thyroid Carcinomas of Follicular Cell Origin. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 683-691.	2.5	72
64	PLAG1 immunohistochemistry is a sensitive marker for pleomorphic adenoma: a comparative study with <i>PLAG1</i> genetic abnormalities. <i>Histopathology</i> , 2018, 72, 285-293.	2.9	71
65	Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic Tj ETQq1 1 0.784314 rgBT/Overlock 10 Tf 50	2.0	68
66	Prognostic Factors in Myoepithelial Carcinoma of Salivary Glands. <i>American Journal of Surgical Pathology</i> , 2015, 39, 931-938.	3.7	68
67	Effective Intravenous Therapy of Murine Pulmonary Metastases with an Oncolytic Herpes Virus Expressing Interleukin 12. <i>Clinical Cancer Research</i> , 2004, 10, 251-259.	7.0	63
68	Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. <i>Cancer Research</i> , 2018, 78, 4642-4657.	0.9	60
69	Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. <i>Cancer</i> , 2017, 123, 4114-4121.	4.1	59
70	Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. <i>Surgery</i> , 2006, 140, 899-906.	1.9	58
71	Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell-derived thyroid carcinomas: a clinicopathologic study of 276 cases. <i>Human Pathology</i> , 2015, 46, 1789-1798.	2.0	58
72	The utility of p16 immunostaining in fine needle aspiration in p16-positive head and neck squamous cell carcinoma. <i>Human Pathology</i> , 2016, 54, 193-200.	2.0	57

#	ARTICLE	IF	CITATIONS
73	<i>EIF1AX</i> and <i>RAS</i> Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC. <i>Cancer Discovery</i> , 2019, 9, 264-281.	9.4	57
74	Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting <i>ETV6</i> - <i>NTRK3</i> fusion. <i>Histopathology</i> , 2020, 76, 375-382.	2.9	57
75	<i>SWI/SNF</i> Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies. <i>Cancer Discovery</i> , 2021, 11, 1158-1175.	9.4	57
76	Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category?. <i>Endocrine</i> , 2018, 59, 143-150.	2.3	57
77	International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 96-104.	1.6	57
78	Pediatric Differentiated Thyroid Carcinoma of Follicular Cell Origin: Prognostic Significance of Histologic Subtypes. <i>Thyroid</i> , 2016, 26, 219-226.	4.5	56
79	Inter-Observer Variation in the Pathologic Identification of Minimal Extrathyroidal Extension in Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2016, 26, 512-517.	4.5	56
80	Encapsulated Malignant Follicular Cell-Derived Thyroid Tumors. <i>Endocrine Pathology</i> , 2010, 21, 212-218.	9.0	54
81	Poorly Differentiated Thyroid Carcinoma Presenting with Gross Extrathyroidal Extension: 1986-2009 Memorial Sloan-Kettering Cancer Center Experience. <i>Thyroid</i> , 2013, 23, 997-1002.	4.5	54
82	Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas. <i>Thyroid</i> , 2016, 26, 1588-1597.	4.5	53
83	Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics. <i>Thyroid</i> , 2017, 27, 632-640.	4.5	52
84	Prognostic Factors in Papillary Microcarcinoma with Emphasis on Histologic Subtyping: A Clinicopathologic Study of 148 Cases. <i>Thyroid</i> , 2014, 24, 245-253.	4.5	51
85	Salivary gland epithelial neoplasms in pediatric population: a single-institute experience with a focus on the histologic spectrum and clinical outcome. <i>Human Pathology</i> , 2017, 67, 37-44.	2.0	51
86	Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers. <i>Journal of Clinical Investigation</i> , 2018, 128, 4086-4097.	8.2	49
87	Microscopic Positive Margins in Differentiated Thyroid Cancer Is Not an Independent Predictor of Local Failure. <i>Thyroid</i> , 2015, 25, 993-998.	4.5	46
88	Metastatic solid tumors to the jaw and oral soft tissue: A retrospective clinical analysis of 44 patients from a single institution. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2016, 44, 1047-1053.	1.7	46
89	Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma?. <i>Surgery</i> , 2020, 167, 10-17.	1.9	46
90	Higher Administered Activities of Radioactive Iodine Are Associated with Less Structural Persistent Response in Older, but Not Younger, Papillary Thyroid Cancer Patients with Lateral Neck Lymph Node Metastases. <i>Thyroid</i> , 2014, 24, 1088-1095.	4.5	45

#	ARTICLE	IF	CITATIONS
91	The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). <i>Human Pathology</i> , 2018, 74, 1-4.	2.0	45
92	Misinterpreted Myoepithelial Carcinoma of Salivary Gland. <i>American Journal of Surgical Pathology</i> , 2019, 43, 601-609.	3.7	44
93	Prognostic Value of Vascular Invasion in Well-Differentiated Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2015, 25, 503-508.	4.5	43
94	The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma. <i>Histopathology</i> , 2019, 75, 672-682.	2.9	43
95	Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers. <i>Nature Biomedical Engineering</i> , 2020, 4, 272-285.	22.5	43
96	Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. <i>Modern Pathology</i> , 2020, 33, 1690-1701.	5.5	42
97	White adipose tissue inflammation and cancer-specific survival in patients with squamous cell carcinoma of the oral tongue. <i>Cancer</i> , 2016, 122, 3794-3802.	4.1	41
98	Time Course and Predictors of Structural Disease Progression in Pulmonary Metastases Arising from Follicular Cell-Derived Thyroid Cancer. <i>Thyroid</i> , 2016, 26, 518-524.	4.5	41
99	Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules. <i>Surgery</i> , 2019, 165, 17-24.	1.9	41
100	Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases. <i>Histopathology</i> , 2022, 80, 322-337.	2.9	41
101	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. <i>Head and Neck</i> , 2022, 44, 1277-1300.	2.0	41
102	Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG). <i>American Journal of Surgical Pathology</i> , 2020, 44, 545-552.	3.7	39
103	Primary squamous cell carcinoma within a solitary nonparasitic hepatic cyst. <i>Journal of Surgical Oncology</i> , 1994, 57, 210-212.	1.7	38
104	Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3110-3116.	7.0	36
105	The prognostic role of histologic grade, worst pattern of invasion, and tumor budding in early oral tongue squamous cell carcinoma: a comparative study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 597-606.	2.8	36
106	Encapsulated Thyroid Carcinoma of Follicular Cell Origin. <i>Endocrine Pathology</i> , 2015, 26, 191-199.	9.0	35
107	Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocyctic features. <i>Endocrine</i> , 2019, 64, 97-108.	2.3	35
108	How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. <i>Thyroid</i> , 2019, 29, 1792-1803.	4.5	33

#	ARTICLE	IF	CITATIONS
109	Pathologic Reporting of Tall-Cell Variant of Papillary Thyroid Cancer: Have We Reached a Consensus?. <i>Thyroid</i> , 2017, 27, 1498-1504.	4.5	32
110	Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management. <i>European Journal of Surgical Oncology</i> , 2018, 44, 338-347.	1.0	32
111	Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon. <i>Human Pathology</i> , 2017, 65, 133-139.	2.0	30
112	Enhancing Radioiodine Incorporation in <i>BRAF</i> -Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. <i>Thyroid</i> , 2022, 32, 273-282.	4.5	30
113	Histologic spectrum of polymorphous adenocarcinoma of the salivary gland harbor genetic alterations affecting PRKD genes. <i>Modern Pathology</i> , 2020, 33, 65-73.	5.5	29
114	Poorly differentiated thyroid carcinoma. <i>Seminars in Diagnostic Pathology</i> , 2020, 37, 243-247.	1.5	29
115	Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance. <i>Human Pathology</i> , 2019, 93, 30-36.	2.0	27
116	Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node Metastases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4889-4899.	3.6	26
117	Molecular detection and characterization of circulating tumor cells and micrometastases in prostatic, urothelial, and renal cell carcinomas. <i>Journal of Surgical Oncology</i> , 2001, 20, 304-311.	1.4	24
118	Detection and assessment of capsular invasion, vascular invasion and lymph node metastasis volume in thyroid carcinoma using microCT scanning of paraffin tissue blocks (3D whole block imaging): a proof of concept. <i>Modern Pathology</i> , 2020, 33, 2449-2457.	5.5	23
119	de Quervain's thyroiditis: A review of experience with surgery. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2016, 37, 534-537.	1.3	22
120	Interobserver Variability in the Histopathologic Assessment of Extrathyroidal Extension of Well Differentiated Thyroid Carcinoma Supports the New American Joint Committee on Cancer Eighth Edition Criteria for Tumor Staging. <i>Thyroid</i> , 2019, 29, 619-624.	4.5	22
121	The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma. <i>Modern Pathology</i> , 2019, 32, 205-215.	5.5	22
122	A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3618-3630.	6.4	21
123	Characterization of Subtypes of <i>BRAF</i> -Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1030-1039.	3.6	21
124	Data set for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting. <i>Human Pathology</i> , 2021, 110, 62-72.	2.0	20
125	Prophylactic Lateral Neck Dissection for Medullary Thyroid Carcinoma is not Associated with Improved Survival. <i>Annals of Surgical Oncology</i> , 2021, 28, 6572-6579.	1.5	18
126	Transposon mutagenesis identifies chromatin modifiers cooperating with <i>Ras</i> in thyroid tumorigenesis and detects <i>ATXN7</i> as a cancer gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4951-E4960.	7.1	17

#	ARTICLE	IF	CITATIONS
127	Crucial parameters in thyroid carcinoma reporting â€œ challenges, controversies and clinical implications. <i>Histopathology</i> , 2018, 72, 32-39.	2.9	17
128	Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): An Update. <i>Head and Neck Pathology</i> , 2020, 14, 303-310.	2.6	17
129	Follicular and Hurthle Cell Carcinoma: Comparison of Clinicopathological Features and Clinical Outcomes. <i>Thyroid</i> , 2022, 32, 245-254.	4.5	17
130	A proportion of primary squamous cell carcinomas of the parotid gland harbour high-risk human papillomavirus. <i>Histopathology</i> , 2016, 69, 921-929.	2.9	15
131	Fluorescence-guided resection of tumors in mouse models of oral cancer. <i>Scientific Reports</i> , 2020, 10, 11175.	3.3	15
132	Mitonuclear genotype remodels the metabolic and microenvironmental landscape of Hurthle cell carcinoma. <i>Science Advances</i> , 2022, 8, .	10.3	15
133	Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy. <i>Molecular Cancer Research</i> , 2022, 20, 45-55.	3.4	13
134	Inter-Observer Variation in the Pathologic Identification of Extranodal Extension in Nodal Metastasis from Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2016, 26, 816-819.	4.5	12
135	NRAS Q61R immunohistochemical staining in thyroid pathology: sensitivity, specificity and utility. <i>Histopathology</i> , 2021, 79, 650-660.	2.9	12
136	Clinicopathologic features and outcome of head and neck mucosal spindle cell squamous cell carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 729-739.	2.8	11
137	Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. <i>Cancer</i> , 1996, 78, 10-16.	4.1	10
138	The solid variant of papillary thyroid carcinoma: a multi-institutional retrospective study. <i>Histopathology</i> , 2022, 81, 171-182.	2.9	9
139	Undetectable Thyroglobulin Levels in Poorly Differentiated Thyroid Carcinoma Patients Free of Macroscopic Disease After Initial Treatment: Are They Useful?. <i>Annals of Surgical Oncology</i> , 2015, 22, 4193-4197.	1.5	8
140	Critical Prognostic Parameters in the Anatomic Pathology Reporting of Differentiated Follicular Cell-Derived Thyroid Carcinoma. <i>Cancers</i> , 2019, 11, 1100.	3.7	8
141	Solitary Extramedullary Plasmacytoma of the Cricoid Cartilageâ€”Case Report. <i>Frontiers in Oncology</i> , 2017, 7, 284.	2.8	7
142	Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 4423-4429.	1.5	6
143	Depth of invasion versus tumour thickness in early oral tongue squamous cell carcinoma: which measurement is the most practical and predictive of outcome?. <i>Histopathology</i> , 2021, 79, 325-337.	2.9	6
144	Recurrent Differentiated Thyroid Carcinoma: Biological Implications of Age, Method of Detection, and Site and Extent of Recurrence. <i>Annals of Surgical Oncology</i> , 2002, 9, 789-798.	1.5	6

#	ARTICLE	IF	CITATIONS
145	Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 382-394.	4.1	6
146	Primary Mesenchymal Tumors of the Thyroid Gland: A Modern Retrospective Cohort Including the First Case of TFE3-Translocated Malignant Perivascular Epithelioid Cell Tumor (PEComa). <i>Head and Neck Pathology</i> , 2022, , 1.	2.6	6
147	The contribution of molecular pathology to the classification of thyroid tumors. <i>Diagnostic Histopathology</i> , 2018, 24, 87-94.	0.4	5
148	Nodal characteristics associated with adverse prognosis in oral cavity cancer are linked to host immune status. <i>Journal of Surgical Oncology</i> , 2021, 123, 141-148.	1.7	5
149	Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer. <i>Cancer</i> , 2019, 125, 2984-2990.	4.1	4
150	Histologic evaluation of host immune microenvironment and its prognostic significance in oral tongue squamous cell carcinoma: a comparative study on lymphocytic host response (LHR) and tumor infiltrating lymphocytes (TILs). <i>Pathology Research and Practice</i> , 2021, 228, 153473.	2.3	4
151	A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 799-806.	4.5	4
152	Diagnostic discrepancy in second opinion reviews of primary epithelial neoplasms involving salivary gland: An 11-year experience from a tertiary referral center focusing on useful pathologic approaches and potential clinical impacts. <i>Head and Neck</i> , 2021, 43, 2497-2509.	2.0	2
153	HPV-related head and neck cancers: Pathology and biology. <i>Journal of Surgical Oncology</i> , 2021, 124, 923-930.	1.7	2
154	Recipient of the 2021 Endocrine Pathology Society Lifetime Achievement Award: Dr. Ronald A. DeLellis. <i>Endocrine Pathology</i> , 2021, 32, 429-431.	9.0	2
155	Lymphovascular invasion and active surveillance in thyroid cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1775-1776.	1.0	0
156	Hurthle Cell Adenoma and Carcinoma. , 2011, , 1764-1766.		0
157	Hurthle Cell Adenoma and Carcinoma. , 2014, , 1-3.		0
158	Hurthle Cell Adenoma and Carcinoma. , 2017, , 2157-2159.		0